Table 5.

Hypercortisolism treatment.

Case number	1st line treatment		2nd line treatment		3rd line treatment		Final state of CS
	Drug	Response	Drug	Response	Drug	Response
1	Metyrapone (250 mg TID)+ long-acting SST analogue (pasireotide 0,6 mg BID SC)	P	-	-	-	-	Uncontrolled
2	Ketoconazole (200 mg TID)	CC	-	-	-	-	Cured
3	Ketoconazole (200 mg TID)	P until Qx	Ketoconazole (200 mg TID) + long acting SST (octreotide 20 mg/28d SC)	P until Qx	Ketoconazole (200 mg TID) + long acting SST (octreotide 20 mg/28d SC) + metyrapone (500 mg BID)	P until Qx	Cured
4	Ketoconazole (200 mg BID)	PC	-	-		-	Uncontrolled
5	Ketoconazole (NA)	P until Qx	-	-	-	-	Cured
6	Ketoconazole (400 mg BID)	P	Ketoconazole (400 mg BID) + metyrapone (250 mg TID)	P	-	-	Uncontrolled
7	Ketoconazole (200 mg TID)	P	-	-	-	-	Uncontrolled
8	Ketoconazole (200 mg TID)	P	Metyrapone (250 mg TID)	PC	-	-	Uncontrolled
9	Metyrapone (500 mg BID)	PC until Qx	-	-	-	-	Cured
10	Ketoconazole (200 mg BID)	PC until Qx	-	-	-	-	Cured
11	Ketoconazole (200 mg TID)	P	-	-	-	-	Uncontrolled
12	Metyrapone (500 mg QID)	P	-	-	-	-	Uncontrolled

SST, somatostatin; P, persistence; CC, complete control; PC, partial control; Qx, surgery; CS, Cushing’s syndrome.